NCT03013491 2025-06-17PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasCytomX TherapeuticsPhase 1/2 Terminated196 enrolled 28 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT01769222 2024-01-24Ipilimumab and Local Radiation for Selected Solid TumorsStanford UniversityPhase 1 Terminated3 enrolled 5 charts
NCT02675439 2021-12-30Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or LymphomasChinook Therapeutics, Inc.Phase 1 Terminated47 enrolled
NCT00089076 2014-05-30MDX-010 in Treating Patients With Recurrent or Refractory LymphomaNational Cancer Institute (NCI)Phase 1/2 Terminated18 enrolled 11 charts